114 related articles for article (PubMed ID: 6896222)
1. [Serum free thyroxine after 131I therapy for Graves' disease (author's transl)].
Saito S; Sakurada T; Fukazawa H; Yoshida K; Kaise N; Kitaoka H; Yamamoto M; Kaise K
Kaku Igaku; 1981 Dec; 18(10):1421-4. PubMed ID: 6896222
[No Abstract] [Full Text] [Related]
2. Triiodothyronine suppression tests and TSH-releasing hormone tests before and after I- 131 therapy for Graves' disease.
Tamai H; Nakagawa T; Takahashi H; Ohsako N; Fukino O; Shinzato R; Suematsu H; Matsuzuka F; Kuma K; Nagataki S
J Nucl Med; 1980 Mar; 21(3):240-5. PubMed ID: 6892713
[No Abstract] [Full Text] [Related]
3. [Impact of pretreatment variables on the outcome of standardized 131I therapy with 150 Gray in Graves' disease].
Pfeilschifter J; Elser H; Haufe S; Ziegler R; Georgi P
Nuklearmedizin; 1997 Apr; 36(3):81-6. PubMed ID: 9162906
[TBL] [Abstract][Full Text] [Related]
4. Discordant hypothyroxinemia and hypertriiodothyroninemia in treated patients with hyperthyroid Graves' disease.
Chen JJ; Ladenson PW
J Clin Endocrinol Metab; 1986 Jul; 63(1):102-6. PubMed ID: 2423547
[TBL] [Abstract][Full Text] [Related]
5. [Changes in serum T3, T4 and TSH before and after the T3-suppression test in patients treated for Graves' disease (author's transl)].
Tamai H; Suematsu H; Esaki M; Kurakawa N; Aoki H
Nihon Naibunpi Gakkai Zasshi; 1977 Jan; 53(1):17-27. PubMed ID: 72007
[No Abstract] [Full Text] [Related]
6. Serum levels of the cytokines IL-1beta, IL-6 and ICAM-1 after 131I-treatment of Graves' disease and nodular goiter.
Nygaard B; Jarløv AE; Kristensen LO; Faber J
Horm Metab Res; 2000 Jul; 32(7):283-7. PubMed ID: 10965935
[TBL] [Abstract][Full Text] [Related]
7. Hyperthyroidism due to Graves-Basedow disease in a woman refractory to thyroid hormones.
González Cabrera N; Kalic AK; Antón Miguel MÁ; Sierra Polo P; Vicente Vicente MÁ
Endocrinol Nutr; 2012 Dec; 59(10):609-11. PubMed ID: 22425314
[No Abstract] [Full Text] [Related]
8. Iodine-131 given for therapeutic purposes modulates differently interferon-gamma-inducible alpha-chemokine CXCL10 serum levels in patients with active Graves' disease or toxic nodular goiter.
Antonelli A; Rotondi M; Fallahi P; Grosso M; Boni G; Ferrari SM; Romagnani P; Serio M; Mariani G; Ferrannini E
J Clin Endocrinol Metab; 2007 Apr; 92(4):1485-90. PubMed ID: 17244787
[TBL] [Abstract][Full Text] [Related]
9. Unresponsiveness to thyrotropin-releasing hormone (TRH) in treated Graves' hyperthyroidism and in euthyroid Graves' disease.
Clifton-Bligh P; Silverstein GE; Burke G
J Clin Endocrinol Metab; 1974 Apr; 38(4):531-8. PubMed ID: 4206830
[No Abstract] [Full Text] [Related]
10. Discordant hypothyroxinemia and hypertriiodothyroninemia in treated patients with hyperthyroid Graves' disease and toxic multinodular goiter.
Gedik O; Ozdemir T; Akalin S
Isr J Med Sci; 1991 Jul; 27(7):361-4. PubMed ID: 1712765
[TBL] [Abstract][Full Text] [Related]
11. [Serum thyroid hormones and TSH response to TRH during treatment of Graves' disease by carbimazole (author's transl)].
Lorcy Y; Heim J; Auvray E; Allannic H
Ann Endocrinol (Paris); 1979; 40(4):441-2. PubMed ID: 117739
[TBL] [Abstract][Full Text] [Related]
12. Changes in serum TSH and T4 after T3 suppression tests in patients treated for hyperthyroidism due to Graves' disease.
Suematsu H; Tamai H; Esaki M; Kurokawa N; Aoki H; Matsuzuka F; Miyauchi A; Kuma K
J Clin Endocrinol Metab; 1977 Nov; 45(5):1013-8. PubMed ID: 579181
[No Abstract] [Full Text] [Related]
13. Effect of methimazole pretreatment on serum thyroid hormone levels after radioactive treatment in Graves' hyperthyroidism.
Andrade VA; Gross JL; Maia AL
J Clin Endocrinol Metab; 1999 Nov; 84(11):4012-6. PubMed ID: 10566642
[TBL] [Abstract][Full Text] [Related]
14. Correlation of long-acting thyroid stimulator with serum levels of tri-iodothyronine, thyroxine and thyrotropin in Graves' disease.
Sawhney RC; Kannan V; Rastogi GK
J Assoc Physicians India; 1975 Feb; 23(2):111-4. PubMed ID: 1242389
[No Abstract] [Full Text] [Related]
15. Clinical practice. Graves' disease.
Brent GA
N Engl J Med; 2008 Jun; 358(24):2594-605. PubMed ID: 18550875
[No Abstract] [Full Text] [Related]
16. T lymphocyte subpopulations in Graves' disease: relationship with clinical conditions.
Bagnasco M; Canonica GW; Ferrini S; Biassoni P; Melioli G; Ferrini O; Giordano G
Acta Endocrinol (Copenh); 1983 Feb; 102(2):213-9. PubMed ID: 6187169
[TBL] [Abstract][Full Text] [Related]
17. Short-term effect of radioactive iodine therapy on CXCL-10 production in Graves' disease.
Dong QY; Li SJ; Gao GQ; Liu XM; Li WX; Liang CG; Du WH; Wsng YL
Clin Invest Med; 2011 Oct; 34(5):E262. PubMed ID: 21968267
[TBL] [Abstract][Full Text] [Related]
18. Factors influencing the relationship between labelled triiodothyronine and thyroxine levels in the serum of patients with Graves' disease.
Földes J; Gyertyánfy G; Tako J; Bános C; Gesztesi E
Endokrinologie; 1973 Jan; 61(1):52-64. PubMed ID: 4739850
[No Abstract] [Full Text] [Related]
19. Methimazole, but not betamethasone, prevents 131I treatment-induced rises in thyrotropin receptor autoantibodies in hyperthyroid Graves' disease.
Gamstedt A; Wadman B; Karlsson A
J Clin Endocrinol Metab; 1986 Apr; 62(4):773-7. PubMed ID: 2869050
[TBL] [Abstract][Full Text] [Related]
20. Normal serum triiodothyronine concentration and the lack of TSH response to TRH in patients with euthyroid Graves' disease.
Shimizu T; Shishiba Y
Endocrinol Jpn; 1973 Oct; 20(5):527-8. PubMed ID: 4209648
[No Abstract] [Full Text] [Related]
[Next] [New Search]
